Hutch News

Hutch News

Stories tagged 'Oliver Press'

Dr. Phil Greenberg named 2018 Leader in Health Care

Seattle Business Magazine honors cancer immunotherapy pioneer for his work on T-cell therapy

March 2, 2018 | By Susan Keown / Fred Hutch News Service

Seattle Business Magazine honors Fred Hutch cancer immunotherapy pioneer Dr. Phil Greenberg with 2018 Leaders in Health Care Gold Award for Achievement in Medical Research.

View story >


How cancer survivors are teaching researchers — even decades later

Tracking survivors long after treatment ends helps inform medical decisions for today’s patients and much more

Jan. 26, 2018 | By Rachel Tompa / Fred Hutch News Service

Every year since its inception in the early 1980s, the Fred Hutch Long-term Follow-up Program sends out a detailed questionnaire to every transplant survivor. The answers to these questions inform a host of research topics on the long-term effects of transplantation, from graft-vs.-host disease to cataracts, from secondary cancers to infertility and sexual dysfunction.

View story >


Mourning the loss of Dr. Oliver 'Ollie' Press

Lymphoma physician-scientist, leader and mentor made lifesaving contributions to the development of targeted cancer therapies

Oct. 2, 2017 | by Susan Keown / Fred Hutch News Service

Dr. Oliver Press died of complications from glioma, a brain cancer. Press was a physician-scientist who made foundational contributions to the development of targeted therapies for blood cancers.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Sept. 14, 2017

An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.

View story >


Good News at Fred Hutch

American Society of Hematology to recognize Dr. Oliver Press for outstanding mentorship

Aug. 24, 2017

The American Society of Hematology, or ASH, announced that Fred Hutch’s Dr. Oliver “Ollie” Press, an internationally known expert in lymphoma and other blood cancers, will receive an award for outstanding mentorship Dec. 10 at the 59th ASH Annual Meeting and Exposition in Atlanta.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Aug. 24, 2017

Fred Hutchinson Cancer Research Center bioengineer and cancer researcher Dr. Cyrus Ghajar has focused much of his work on what causes breast cancer cells to metastasize. Now, with the help of a new $1 million grant from the W.M. Keck Foundation, Ghajar and his team are hoping to crack open a mystery that has long puzzled scientists in the field: Why do metastatic cells, which can proliferate in many organs, nearly always fail to grow in skeletal muscles, which account for as much as half the body mass of an adult?

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.